Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban

Thrombosis and Haemostasis

Volumn 117, Issue 2, 2017, Pages 238-245

  Ansell, Jack E ^a   Bakhru, Sasha H ^b   Laulicht, Bryan E ^b   Steiner, Solomon S ^b   Grosso, Michael A ^c   Brown, Karen ^c   Dishy, Victor ^c   Lanz, Hans J ^c   Mercuri, Michele F ^c   Noveck, Robert J ^d   Costin, James C ^b  

^a Perosphere Inc ^*  (United States)

^b Perosphere Inc   (United States)

^c DAIICHI SANKYO INC   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulant; Ciraparantag; Edoxaban; Reversal; Whole blood clotting time

Indexed keywords

BILIRUBIN; CIRAPARANTAG; D DIMER; EDOXABAN; ELECTROLYTE; LIVER ENZYME; PHOSPHOTRANSFERASE; PLACEBO; ARGININE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BODY TEMPERATURE SENSATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUSHING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFECTS; DRUG MONITORING; INTRAVENOUS DRUG ADMINISTRATION; NORTH CAROLINA; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ADULT; ARGININE; BLOOD COAGULATION; DOUBLE-BLIND METHOD; DRUG MONITORING; FACTOR XA INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NORTH CAROLINA; PIPERAZINES; PYRIDINES; THIAZOLES; WHOLE BLOOD COAGULATION TIME;

EID: 85011068507     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-03-0224     Document Type: Article

References (13)

1. Weitz JI, Eikelboom JW, Samama MM. New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012; 141 (2 Suppl): e120S-e151S.
2. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl 2): S141-S145.
3. Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: Mechanism of action and binding specificity of PER977. Internat’l Soc Thromb & Haemost 2013; Abstract http://www.eventure-online.com/eventure/publicAb stractView.do?id=226718&congressId=6839 and http://www.perosphere.com/ content/presentations/documents/Perosphere_ISTH_Talk.pdf.
4. Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for anticoagulants. Circulation 2012; 126: Abstract #11395.
5. Didisheim P. Tests of blood coagulation and hemostasis: The coagulation (clotting) time. J Am Med Assoc 1966; 198: 1299.
6. Eerenberg ES, Levi M, Buller HR. Contra: Antidotes for novel anticoagulants? Do we really need them. Thromb Haemost 2012; 108: 623–624.
7. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014; 111: 189–198.
8. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554–3562.
9. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm467300.htm. Accessed March 9, 2016.
10. Lu G, DeGuzman FR, Hollenbach SJ, et al. A novel antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446–451.
11. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511–520.
12. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413–2424.
13. Ansell J. Blocking Bleeding: Reversing Anticoagulant Therapy. Nat Med 2013; 19: 402–404.